Omidenepag Isopropyl — Active Pharmaceutical Ingredient

Omidenepag Isopropyl is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: SOLUTION. Routes: OPHTHALMIC.

This content is for informational purposes only. Always consult a healthcare professional.

Omidenepag Isopropyl (1 brand name, 1 dosage form, 1 route)

Available dosage forms: SOLUTION.

Routes of administration: OPHTHALMIC.

Brand Names

  • OMLONTI

Indications and Usage

Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Contraindications

None.

Adverse Reactions

The following clinically significant adverse reactions are described elsewhere in the labeling: Pigmentation [see Warnings and Precautions (5.1)] Eyelash Changes [see Warnings and Precautions (5.2)] Ocular Inflammation [see Warnings and Precautions (5.3)] Macular Edema [see Warnings and Precautions (5.4)]

Mechanism of Action

Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.